Showing results (571-580 of 3,348) with videos related to

Sort By:
Pageof 335
Pharmacoeconomics|May 10, 2007
The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD): responsiveness to change and English language validationPeter Wahlqvist, Gordon H Guyatt, David Armstrong, et al.
Pharmacoeconomics|May 10, 2007
Costs of a community pharmacist-led medicines management service for patients with coronary heart disease in England: healthcare system and patient perspectivesAnthony Scott, Michela Tinelli, Christine Bond, et al.
Pharmacoeconomics|May 26, 2007
Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenariosStefan Gress, Dea Niebuhr, Uwe May, et al.
Pharmacoeconomics|September 1, 2006
Accuracy versus transparency in pharmacoeconomic modelling: finding the right balanceDavid M Eddy
Pharmacoeconomics|September 1, 2006
Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharingJohn H Wlodarczyk, Leslie G Cleland, Anne M Keogh, et al.
Pharmacoeconomics|November 30, 2006
Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosisHege Urdahl, Andrea Manca, Mark J Sculpher
Pharmacoeconomics|November 30, 2006
Generic health-related quality-of-life assessment in children and adolescents: methodological considerationsUlrike Ravens-Sieberer, Michael Erhart, Nora Wille, et al.
Pharmacoeconomics|November 30, 2006
Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertensionGreg L Plosker, Susan J Keam
Pharmacoeconomics|April 28, 2005
Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literatureHelen Doll, Marc Miravitlles
Pharmacoeconomics|April 28, 2005
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costsPeter K Schädlich, Henning Zeidler, Angela Zink, et al.
Pageof 335